Pharmaceutical Research and Manufacturers of America

With Biden’s Agenda in the Balance, Lobbying Kicks Into High Gear

Business interests are using ads and other efforts to cajole Democrats to change or kill a $3.5 trillion social policy bill.

With Biden’s Agenda in the Balance, Lobbying Kicks Into High Gear

Business interests are using ads and other efforts to cajole Democrats to change or kill a $3.5 trillion social policy bill.

With Biden’s Agenda in the Balance, Lobbying Kicks Into High Gear

Business interests are using ads and other efforts to cajole Democrats to change or kill a $3.5 trillion social policy bill.

With Biden’s Agenda in the Balance, Lobbying Kicks Into High Gear

Business interests are using ads and other efforts to cajole Democrats to change or kill a $3.5 trillion social policy bill.

Is COVID the Rx for the Pharmaceutical Industry’s Reputation?

Darlene Dobry, Strategic Advisor, Medical Devices and Pharmaceuticals As the COVID-19 pandemic continues to bring the world’s economies, healthcare systems, and communities to their knees, the Pharma industry appears to be the shining hope to help us return to a new normal. Could the industry’s response to this global public health crisis be the Rx …

Is COVID the Rx for the Pharmaceutical Industry’s Reputation? Read More »